Daewoong Pharmaceutical, a leading healthcare company in Korea, has announced the official launch of its high-purity, high-quality botulinum toxin product, NABOTA, in Saudi Arabia.
The launch follows a rigorous quality evaluation process conducted by the Saudi Food and Drug Authority (SFDA). As recognised with approvals from the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada, Daewoong Pharmaceutical's botulinum toxin has demonstrated outstanding quality and safety. This milestone is expected to serve as a key gateway for Daewoong Pharmaceutical's expansion into the Middle Eastern market.
Daewoong Pharmaceutical aims to meet the needs of patients in Saudi Arabia and the wider Middle Eastern region while expanding its market share. Daewoong Pharmaceutical's premium high-purity botulinum toxin, produced using the patented 'HI-PURE™ Technology' and advanced vacuum drying processes, received FDA approval in 2019, making it the first Asian-manufactured botulinum toxin to gain such recognition.
"NABOTA has the same protein molecular structure as Botox, at 900kDa, and has proven its efficacy and safety through clinical trials and regulatory approvals in advanced markets," said Dr Hassan Galadari, a key opinion leader in the region and dermatologist from the UAE.
